Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points

Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points

Abstract Venetoclax (VEN), a small-molecule inhibitor of B cell leukemia/lymphoma-2, is now FDA approved (November 2018) for use in acute myeloid leukemia (AML), specific to newly diagnosed elderly or unfit patients, in combination with a hypomethylating agent (HMA; including azacitidine or decitabi...

Full description

Bibliographic Details
Main Authors:	Naseema Gangat, Ayalew Tefferi
Format:	Article
Language:	English
Published:	Nature Publishing Group 2020-11-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-020-00388-x

Similar Items

To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia
by: Naseema Gangat, et al.
Published: (2022-04-01)

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
by: Ayalew Tefferi, et al.
Published: (2023-07-01)

Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
by: Mostafa Abdallah, et al.
Published: (2024-03-01)

Clinical Study of Venetoclax with Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
by: CHEN Xiaofeng, WANG Meng, LI Zhongyu, LI Jiajia
Published: (2022-03-01)

Venetoclax Resistance in Acute Myeloid Leukemia
by: Sylvain Garciaz, et al.
Published: (2024-03-01)

Venetoclax in adult acute myeloid leukemia
by: Mengci Hu, et al.
Published: (2023-12-01)

Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms
by: Mithun Vinod Shah, et al.
Published: (2022-07-01)

P544: MOLECULAR PREDICTORS OF RESPONSE AND SURVIVAL IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA FOLLOWING VENETOCLAX AND HYPOMETHYLATING AGENTS
by: I. Johnson, et al.
Published: (2022-06-01)

Infections of Venetoclax-Based Chemotherapy in Acute Myeloid Leukemia: Rationale for Proper Antimicrobial Prophylaxis
by: Raeseok Lee, et al.
Published: (2021-12-01)

Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
by: Leiming Xia, et al.
Published: (2023-05-01)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
by: Rimal Ilyas, et al.
Published: (2023-02-01)

P580: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH WT1 MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
by: Rami Basmaci, et al.
Published: (2023-08-01)

Venetoclax combined chemotherapy versus chemotherapy alone for acute myeloid leukemia: a systematic review and meta-analysis
by: Jingkui Zhu, et al.
Published: (2024-03-01)

Venetoclax-containing regimens in acute myeloid leukemia
by: Ibrahim Aldoss, et al.
Published: (2021-02-01)

Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?
by: Ramy Rahmé, et al.
Published: (2024-01-01)

Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
by: Guillaume Richard-Carpentier, et al.
Published: (2019-10-01)

P722: CHARACTERISATION OF PHF6 MUTATIONS IN MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
by: Amrutha Sai Mittapalli, et al.
Published: (2023-08-01)

P734: CLONAL HEIRARCHY AND HETEROGENEITY IN STAG2M MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
by: Bahga Katamesh, et al.
Published: (2023-08-01)

P572: VENETOCLAX AND HYPOMETHYLATING AGENT COMBINATIONS FOR THE TREATMENT OF ADVANCED MYELOPROLIFERATIVE NEOPLASMS AND ACUTE MYELOID LEUKEMIA WITH EXTRAMEDULLARY DISEASE
by: K. Sanber, et al.
Published: (2022-06-01)

U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity
by: Talha Badar, et al.
Published: (2023-09-01)

P747: CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
by: Muhamad Oum, et al.
Published: (2023-08-01)

PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
by: Amer M Zeidan, et al.
Published: (2023-08-01)

Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia
by: Carlos Rodríguez-Medina, et al.
Published: (2024-01-01)

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies
by: Mila S. Griffioen, et al.
Published: (2022-07-01)

Phosphoproteomic Characterization and Kinase Signature Predict Response to Venetoclax Plus 3+7 Chemotherapy in Acute Myeloid Leukemia
by: Jie Jin, et al.
Published: (2024-03-01)

Combined Ruxolitinib and Venetoclax Treatment in a Patient with a BCR-JAK2 Rearranged Myeloid Neoplasm
by: Coen J. Lap, et al.
Published: (2021-01-01)

Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
by: Renshi Kawakatsu, et al.
Published: (2024-02-01)

TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms
by: Mithun Vinod Shah, et al.
Published: (2023-04-01)

Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia
by: Emmanuella Oyogoa, et al.
Published: (2023-07-01)

Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
by: Simona De Gregori, et al.
Published: (2023-06-01)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
by: Serena Brancati, et al.
Published: (2021-12-01)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
by: Ian M. Bouligny, et al.
Published: (2023-05-01)

Hymeglusin Enhances the Pro-Apoptotic Effects of Venetoclax in Acute Myeloid Leukemia
by: Cheng Zhou, et al.
Published: (2022-06-01)

Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
by: Aref Al-Kali, et al.
Published: (2023-04-01)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
by: Maansi Joshi, et al.
Published: (2021-03-01)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
by: Naseema Gangat, et al.
Published: (2023-01-01)

P510: PREDICTORS OF RESPONSE AND OUTCOME IN PATIENTS WITH REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA RECEIVING VENETOCLAX WITH NON-INTENSIVE CHEMOTHERAPY
by: Katja Krüger, et al.
Published: (2023-08-01)

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
by: Bachar Samra, et al.
Published: (2020-11-01)

Mayo Clinic experience with 1123 adults with acute myeloid leukemia
by: Kebede H. Begna, et al.
Published: (2021-03-01)

Venetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients
by: Elena Chatzikalil, et al.
Published: (2024-04-01)